dm+d

Unassigned

New Medicines

Prevention of the first invasive extraintestinal pathogenic E. coli disease event caused by ExPEC9V O-serotypes

Information

Vaccine
Janssen-Cilag
Janssen-Cilag

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A 9 valent bioconjugate vaccine, given in a single dose.
E. coli is a leading cause of bacteraemia worldwide. The most common source in adults is the urinary tract. 2-6% of patients who undergo transrectal prostate biopsy develop infectious complications, which can include bacteremia, and fluoroquinolone-resistant ExPEC strains colonizing the rectum are the most common source. The overall annual incidence of E. coli bacteremia in adults ranges between 30 and 50 cases per 100,000 population but increases markedly with age [1].
Prevention of the first invasive extraintestinal pathogenic E. coli disease event caused by ExPEC9V O-serotypes
Intramuscular